BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Is CRA International’s New Bria-IMT Role Quietly Redefining Its Healthcare Moat and Pricing Power (CRAI)? In July 2026, BriaCell Therapeutics Corp. announced it had engaged Charles River Associates (CRA International) and Kaleio, Inc. to support commercial strategy, market access evaluation, and brand planning for Bria-IMT, its investigational metastatic breast cancer therapy currently in a pivotal Phase 3 trial. This engagement highlights how CRA International’s specialized healthcare and market access expertise is being tapped early in the oncology commercialization process, underscoring its... | ||
BriaCell Presenting Final Phase 2, Ongoing Phase 3 Data at ASCO Meeting BriaCell Therapeutics (BCT.TO) Monday said it is presenting final Phase 2 data from its Bria-IMT tri | MMT Newswires | |
BriaCell Therapeutics Completes Manufacturing Bria-PROS+ Clinical Supplies BriaCell Therapeutics (BCT.TO), down near 1% in U.S. pre-market trade, has completed manufacturing | MMT Newswires | |
BriaCell Says FDA Clears Way For Bria-BRES+ Phase 1/2a Study BriaCell Therapeutics (BCT.TO) has received FDA approval to initiate clinical evaluation of its next | MMT Newswires | |
Top Midday Decliners TryHard (THH) unveiled on Wednesday an equity purchase agreement in which Summer Explorer Investment | MMT Newswires | |
Big Bank Earnings, Inflation Data in Focus as US Equity Futures Slip Pre-Bell US equity futures were down ahead of Wednesday's opening bell as traders digested more bank earnings | MMT Newswires | |
Top Midday Gainers XTL Biopharmaceuticals (XTLB) unveiled on Tuesday a binding agreement to acquire 85% of NeuroNOS, a | MMT Newswires | |
 Zacks.com featured highlights include Groupon, BriaCell Therapeutics and InnovAge Holding Groupon, BriaCell Therapeutics, and InnovAge shine as Zacks' top November picks for powerful earnings acceleration potential. | ||
 Top 3 Earnings Acceleration Buys for November Groupon, BriaCell Therapeutics and InnovAge stand out with accelerating earnings momentum as November's market optimism approaches. | ||
BriaCell Adds Three Cancer Centres to Phase 3 Study, Works With MSK Accelerator to Advance Bria-OTS+ BriaCell Therapeutics (BCT.TO) said Tuesday it is adding three cancer centers to its Phase 3 clinica | MMT Newswires | |